Spots Global Cancer Trial Database for myelodysplastic syndrome
Every month we try and update this database with for myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | NCT02842827 | Acute Myeloid L... Myelodysplastic... | bomedemstat tretinoin | 18 Years - | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | |
| SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | NCT00487448 | Myelodysplastic... Acute Myeloblas... | Fludarabine Cytarabine G-CSF Idarubicin Peripheral bloo... Bone marrow tra... | - 75 Years | PETHEMA Foundation | |
| A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome | NCT01513317 | Myelodysplastic... | Siltuximab Placebo Best supportive... | 18 Years - | Janssen Research & Development, LLC | |
| Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | NCT06315309 | GVHD,Acute Acute Leukemia Myelodysplastic... Myeloproliferat... | ATG Combined wi... | 18 Years - 60 Years | University of Alabama at Birmingham | |
| Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT01795924 | Acute Myelogeno... Myelodysplastic... | PD-616 | 18 Years - 75 Years | Biosuccess Biotech Co., Ltd. | |
| Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors | NCT00640796 | Leukemia, Myelo... Leukemia, Lymph... Juvenile Myelom... T-cell Lymphobl... Myelodysplastic... | Haploidentical ... Chemotherapy CliniMACS | - 18 Years | St. Jude Children's Research Hospital | |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | NCT01823198 | Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related... | Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological... | 7 Years - 65 Years | M.D. Anderson Cancer Center | |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome | NCT01053806 | Myelodysplastic... | 5-Azacytidine a... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | NCT00795548 | Myelodysplastic... Acute Myeloid L... | 5-Azacitidine | 18 Years - | Heinrich-Heine University, Duesseldorf | |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | NCT02562443 | Myelodysplastic... MDS Refractory Anem... RAEB | rigosertib Any approved or... best supportive... best supportive... | 18 Years - 81 Years | Traws Pharma, Inc. | |
| Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome | NCT01311258 | Acute Myeloid L... Myelodysplastic... | 18 Years - | University of Rochester | ||
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | NCT00270881 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... | Cord blood tran... TBI cyclophosphamid... cytarabine | 20 Years - 55 Years | Keio University | |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | NCT06059391 | Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil... | 18 Years - | City of Hope Medical Center | |
| Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML | NCT00195104 | Myelodysplastic... | Arsenic Trioxid... Cytarabine | 18 Years - | Weill Medical College of Cornell University | |
| A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) | NCT04691141 | Myelodysplastic... | ATG-016 | 18 Years - | Antengene Corporation | |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | NCT00843882 | Anemia Chronic Myelomo... de Novo Myelody... Myelodysplastic... | Bone Marrow Bio... Epoetin Alfa Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | NCT01444742 | Leukemia Myeloproliferat... | Clofarabine Cytarabine | 18 Years - | M.D. Anderson Cancer Center | |
| Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) | NCT01385423 | Acute Myelogeno... Myelodysplastic... | Preparative Reg... Intravenous Rec... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | NCT03272633 | Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat... | Allogeneic Hema... Irradiated Allo... | 18 Years - | Rutgers, The State University of New Jersey | |
| Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor | NCT01598025 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Non-Hodgkins Ly... | total-body irra... thiotepa fludarabine pho... melphalan anti-thymocyte ... allogeneic hema... peripheral bloo... laboratory biom... | - 19 Years | Memorial Sloan Kettering Cancer Center | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | NCT02272478 | Acute Myeloid L... Myelodysplastic... | Arm A Mylotarg ... Arm B Vosaroxin... Arm D Small mol... Arm C DA V FLAG... Arm E CPX-351 (... Arm F DA V IDAC | 60 Years - | Cardiff University | |
| A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | NCT00619099 | Myelodysplastic... | decitabine decitabine | 18 Years - | Eisai Inc. | |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant | NCT03739502 | AML NHL Hodgkin Disease All Myelodysplastic... | Hyperbaric oxyg... | 18 Years - 70 Years | University of Rochester | |
| Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy | NCT02487069 | Acute Leukemia Chronic Myeloid... Myelodysplastic... | HSCT from MSD HSCT from MUD HSCT from HRD Cyclosporin A Methotrexate Antithymocyte g... Mycophenolate m... | 18 Years - 60 Years | Nanfang Hospital, Southern Medical University | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| AHN-12 Biodistribution in Advanced Leukemia | NCT01207076 | Acute Myelogeno... Myelodysplastic... Acute Lymphobla... Chronic Myeloge... | 90Y-AHN-12 | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Study of SyB C-1101 in Patients With Myelodysplastic Syndrome | NCT03495167 | Myelodysplastic... | SyB C-1101 | 20 Years - | SymBio Pharmaceuticals | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT00778375 | Acute Myeloid L... Myelodysplastic... | Clofarabine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT00818649 | Leukemia Myelodysplastic... | bortezomib vorinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) | NCT00038805 | Leukemia | Mylotarg | 55 Years - 75 Years | M.D. Anderson Cancer Center | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | NCT01520805 | Acute Myeloid L... Myelodysplastic... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00136461 | Acute Myelogeno... Myelodysplastic... | All-trans retin... Bryostatin 1 | 18 Years - | Dana-Farber Cancer Institute | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | NCT01474681 | Acute Myelocyti... Acute Lymphocyt... Chronic Myeloge... Myelodysplastic... Chronic Lymphoc... Marginal Zone L... Follicular Lymp... Large-cell Lymp... Lymphoblastic L... Burkitt's Lymph... High Grade Lymp... Mantle-cell Lym... Lymphoplasmacyt... | HSC835 | 10 Years - 55 Years | Novartis | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | NCT00689000 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CHR-2797 (tosed... | 18 Years - | Chroma Therapeutics | |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | NCT00089596 | Acute Lymphocyt... Acute Myeloid L... Myelodysplastic... Non-Hodgkin Lym... Chronic Myeloge... | Expansion of um... | 12 Years - 60 Years | ViaCell | |
| Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | NCT03150004 | Acute Myeloid L... Myelodysplastic... | Cladribine, Cyt... Cladribine and ... | 18 Years - | Medical College of Wisconsin | |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | NCT02381548 | Acute Myeloid L... Blast Phase Chr... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Chron... Refractory Acut... Refractory Chro... Secondary Acute... Therapy-Related... Untreated Adult... | Adavosertib Belinostat Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) | NCT01048034 | Myelodysplastic... Chronic Myelomo... | Azacitidine Erythropoetin | 18 Years - | Nordic MDS Group | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | NCT03602898 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related... | Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra... | - 65 Years | Fred Hutchinson Cancer Center | |
| Survey on QUality of Life In myeloDisplasia (SQUID) | NCT00967564 | Myelodysplastic... | epidemiologic s... | 18 Years - | Janssen-Cilag S.p.A. | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | NCT03941769 | Acute Myeloid L... Chronic Myeloge... Cord Blood Tran... Myelodysplastic... Myeloproliferat... | Recombinant Int... | 18 Years - | M.D. Anderson Cancer Center | |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | NCT00003838 | Myeloproliferat... Acute Myelogeno... Chronic Myeloge... Myelodysplastic... Acute Lymphobla... | T-cell replete ... Methotrexate Cyclosporine G-CSF | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia | NCT03019939 | Acute Myeloid L... Myelodysplastic... Neutropenia | Isavuconazole | 18 Years - | M.D. Anderson Cancer Center | |
| SARS-CoV-2 Donor-Recipient Immunity Transfer | NCT04666025 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... COVID-19 Infect... Hematopoietic a... Hodgkin Lymphom... Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Biospecimen Col... Diagnostic Labo... Electronic Heal... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | NCT01584531 | Myelodysplastic... MDS Trisomy 8 | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | NCT06013423 | Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid... | Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ... | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. | NCT02663752 | Myelodysplastic... | Bone marrow asp... Deferasirox | 18 Years - | Novartis | |
| L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes | NCT00329498 | Acute Myeloid L... Myelodysplastic... | L-Ascorbic Acid | - | Samsung Medical Center | |
| Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) | NCT00050154 | Myelodysplastic... | ZARNESTRA, tipi... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Phase I Study of Sequential Cord Blood Transplants | NCT00299767 | Lymphoma Leukemia Multiple Myelom... Myelodysplastic... | sequential cord... | - 65 Years | Massachusetts General Hospital | |
| Treosulfan-based Conditioning for Transplantation in AML/MDS | NCT00491634 | Acute Myeloid L... Myelodysplastic... | treosulfan Treosulfan | 18 Years - 68 Years | Sheba Medical Center | |
| Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | NCT01191749 | Leukemia | Alemtuzumab | - | M.D. Anderson Cancer Center | |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | NCT03399773 | Acute Biphenoty... Acute Lymphobla... Chronic Myeloge... Hematopoietic a... Myelodysplastic... Myelodysplastic... | Dilanubicel Cyclophosphamid... Fludarabine Thiotepa Total-Body Irra... Umbilical Cord ... Laboratory Biom... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Multigated Acqu... Electrocardiogr... Computed Tomogr... | 10 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | NCT02494167 | Acute Myeloid L... Myelodysplastic... | MultiTAA-specif... | - | Baylor College of Medicine | |
| Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | NCT02447666 | Myelodysplastic... Leukemia, Myelo... | Azacitidine | 1 Month - 18 Years | Celgene | |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | NCT04083170 | Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem... | Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome | NCT01400633 | Myelodysplastic... | decitabine inje... | 20 Years - | Janssen Korea, Ltd., Korea | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy | NCT01980056 | Myelodysplastic... | Vosaroxin | 18 Years - | Weill Medical College of Cornell University | |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | NCT02877082 | Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt... | Thymoglobulin Bortezomib Tacrolimus | 18 Years - 75 Years | Emory University | |
| The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes | NCT00247026 | Myelodysplastic... | curcumin; coenz... | 16 Years - | Hadassah Medical Organization | |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | NCT01068301 | Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Myelodysplastic... Non-Hodgkin's L... | Plerixafor | - 21 Years | St. Jude Children's Research Hospital | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | NCT05448599 | Acute Myeloid L... Myelodysplastic... | 6MW3211 injecti... | 18 Years - 75 Years | Mabwell (Shanghai) Bioscience Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
